Marie La Russa

Marie La Russa

Auto-generated profile, based on publicly available information

Marie La Russa

Department of Bioengineering, Stanford University, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Science
Verified
Journal Article
Closed access
XLXueqiu Lin
Xueqiu Lin
YLYanxia Liu
Yanxia Liu
SLShuai Liu
Shuai Liu
XZXiang Zhu
Xiang Zhu
LWLingling Wu
Lingling Wu
LQLei S. Qi
Lei S. Qi
Mammalian genomes have multiple enhancers spanning an ultralong distance (>megabases) to modulate important genes, but it is unclear how these enhancers coordinate to achieve this task. We combine multiplexed CRISPRi screening with machine learning to define quantitative enhancer-enhancer interactions. We find that the ultralong distance enhancer network has a nested multilayer architecture that confers functional robustness of gene expression. Experimental characterization reveals that enhancer epistasis is maintained by three-dimensional chromosomal interactions and BRD4 condensation. Machine learning prediction of synergistic enhancers provides an effective strategy to identify noncoding variant pairs associated with pathogenic genes in diseases beyond genome-wide association studies analysis. Our work unveils nested epistasis enhancer networks, which can better explain enhancer functions within cells and in diseases.

1 April 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
XLXueqiu Lin
Xueqiu Lin
YLYanxia Liu
Yanxia Liu
ACAugustine Chemparathy
Augustine Chemparathy
TPTara Pande
Tara Pande
MRMarie La Russa
Marie La Russa
LQLei S. Qi
Lei S. Qi
The COVID-19 pandemic caused by SARS-CoV-2 and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, termed prophylactic antiviral CRISPR in human (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus. Here, we expand in silico analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 crRNAs is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches. We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses in order to facilitate development of CRISPR-based antivirals.